Trastuzumab biosimilar (STC Biologics)

曲妥珠单抗生物类似药 (STC Biologics)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTrastuzumab biosimilar (STC Biologics)

Drug Alias Name曲妥珠单抗生物仿制药 (STC Biologics)STC-101

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesStc Biologics

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesStc Biologics

Active IndicationsN/A

Inactive IndicationsNeoplasms

ATC CodeL01XC03